Cellectis S.A. (NASDAQ:CLLS – Get Free Report)’s stock price passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $3.70 and traded as high as $3.98. Cellectis shares last traded at $3.85, with a volume of 13,554 shares trading hands.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a research report on Monday, April 20th. Citizens Jmp reiterated a “market outperform” rating and issued a $8.00 price target on shares of Cellectis in a research report on Tuesday, April 14th. Finally, Jefferies Financial Group started coverage on shares of Cellectis in a research report on Tuesday, February 17th. They issued a “buy” rating and a $7.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.75.
Read Our Latest Analysis on Cellectis
Cellectis Trading Down 1.8%
Cellectis (NASDAQ:CLLS – Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.08. The company had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $11.04 million. Cellectis had a negative net margin of 89.51% and a negative return on equity of 80.66%.
Hedge Funds Weigh In On Cellectis
Several hedge funds have recently made changes to their positions in CLLS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Cellectis by 228.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after acquiring an additional 3,284,409 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of Cellectis by 132.9% during the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 26,461 shares in the last quarter. Delaney Dennis R bought a new position in shares of Cellectis during the 3rd quarter worth approximately $68,000. B Group Inc. grew its stake in shares of Cellectis by 0.8% during the 3rd quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock worth $9,352,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Cellectis during the 3rd quarter worth approximately $72,000. 63.90% of the stock is owned by institutional investors.
About Cellectis
Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.
The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.
Featured Articles
- Five stocks we like better than Cellectis
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.
